NCT06277804View on ClinicalTrials.gov

A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
Adult Solid Tumor
Interventions
DRUG

LTC004 in Combination With Cyclophosphamide and Fludarabine

LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable

All Listed Sponsors
lead

Letolab

INDUSTRY